Welcome to our dedicated page for Genenta Science S.p.A. SEC filings (Ticker: GNTA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Genenta Science S.p.A. filings document a foreign private issuer reporting on Form 6-K, with disclosures incorporated by reference into its Form F-3 registration statement when specified. The record covers material events, shareholder voting matters, capital-structure updates, operating and financial results, and clinical or regulatory disclosures for its biotechnology platform and Temferon program.
The filings also document governance and corporate-structure actions, including the approved expansion of the company’s corporate purpose to sectors covered by Italian Golden Power legislation, board changes, listing-compliance notices, material agreements, and decisions to streamline subsidiaries and finance-function arrangements as Genenta pursues an Italy- and Europe-focused industrial aggregator strategy.
Genenta Science S.p.A. is closing its wholly owned U.S. subsidiary, Genenta Science, Inc., after a strategic review and a decision to focus on building an industrial aggregator in Italy and Europe. The closure aims to streamline operations, reduce costs, and focus on core markets.
The closure is expected to be substantially completed by July 31, 2026 and is anticipated to result in minimal one-time charges, with no material adverse effect on the company’s overall financial position or liquidity. Former CFO Richard B. Slansky will move from employee to a 12‑month consulting role effective June 1, 2026, continuing as principal financial and accounting officer under a binding consulting agreement that provides fees, healthcare reimbursements, and potential performance-based or equity compensation.
Genenta Science is accelerating its transformation into a biotech, defense, aerospace, and national‑security industrial consolidator by signing definitive agreements to acquire majority ownership of Sòphia High Tech, an Italian aerospace and defense engineering and manufacturing company.
Genenta expects to fund a total of €6.0 million in two tranches. The first tranche combines payments to founders and a €3.25 million reserved capital increase, giving Genenta a 19.9% stake in Sòphia HT; completion of a second tranche would raise its stake to 51%, with an additional potential €0.5 million earnout tied to EBITDA milestones.
Sòphia HT reported approximately €6.29 million in 2024 revenue and other operating income and €0.96 million EBITDA, and preliminarily expects about €8 million in 2025 sales. Over the medium term, it currently targets roughly doubling its 2024 revenue by 2027 and expanding its workforce from 44 to about 70 employees.
Genenta Science S.p.A. has received a Nasdaq notice that its American Depositary Shares no longer meet the exchange’s minimum bid price requirement of $1 per share under Nasdaq Listing Rule 5550(a)(2). The closing bid stayed below this level from February 26 to April 9, 2026.
The company retains its listing for now and has 180 days, until October 7, 2026, to regain compliance. If it qualifies under other Nasdaq Capital Market standards, it may receive an additional 180-day period, potentially using a reverse stock split. Management is evaluating options but cannot assure successful or timely compliance.
Genenta Science S.p.A. reported that its CMO & Head of Development, Francesco Galimi, received a grant of stock options covering 20,000 American Depositary Shares. The options have an exercise price of $0.63 per share and expire on December 31, 2035.
The options vest in equal monthly installments over one year beginning March 30, 2026. Following this grant, Galimi holds stock options for 20,000 ADS directly, reflecting a compensation-related award rather than an open-market transaction.
Genenta Science S.p.A. director Giacomoantonio Paracchi reported a compensation-related grant of stock options. On March 30, 2026, he was awarded options covering 20,000 American Depositary Shares at an exercise price of $0.63 per share, expiring on December 31, 2035.
The options vest in equal monthly installments over one year beginning March 30, 2026, aligning the award with ongoing service. Following this grant, Paracchi holds 20,000 stock options directly.
Genenta Science S.p.A. director Sharei Armon received a grant of stock options for 20,000 American Depositary Shares. The options have an exercise price of $0.63 per share and expire on December 31, 2035. They vest in equal monthly installments over one year beginning March 30, 2026.
Genenta Science S.p.A. director Mutti Miguel Maria received a grant of stock options covering 20,000 American Depositary Shares. The options were granted at no cost, with an exercise price of $0.63 per share and an expiration date of December 31, 2035.
The options vest in equal monthly installments over one year beginning March 30, 2026, aligning the director’s compensation with longer-term company performance. Following this grant, the director holds 20,000 stock options directly, with no open-market share purchases or sales reported in this filing.
Genenta Science S.p.A. reported that Chief Financial Officer Richard B. Slansky received a grant of stock options covering 80,000 American Depositary Shares. The options have an exercise price of $0.63 per share and expire on December 31, 2035.
The award was granted at no cost and is a compensation-related acquisition, not an open-market purchase. According to the footnote, the options vest in equal monthly installments over three years beginning March 30, 2026, and all 80,000 options were reported as held directly following the transaction.
Genenta Science S.p.A. files its Form 20-F annual report for the year ended December 31, 2025, detailing its clinical-stage gene therapy business and strategic shift toward industrial consolidation in national security–related sectors.
The company reports 23,432,183 ordinary shares outstanding as of December 31, 2025 and cash, cash equivalents and marketable securities of about €28.1 million. It remains loss-making, with 2025 net loss of roughly €6.5 million and an accumulated deficit of about €62.6 million.
Genenta highlights substantial financing flexibility, including a $100.0 million shelf registration with approximately $86.0 million remaining and an at-the-market facility with about $26.4 million of capacity left. Extensive risk disclosures emphasize ongoing funding needs, clinical and regulatory uncertainties for Temferon, and execution risks in its planned transformation into a “next-generation strategic industrial consolidator.”
Genenta Science is pursuing a binding offer to acquire up to 51% of Sòphia High Tech, an Italian aerospace and defense manufacturer, by funding EUR 6.0 million through two reserved capital increases and payments to the founders, with the second tranche tied to EBITDA milestones.
The offer includes an initial 30% stake, a performance-based earnout and a 90-day exclusivity period, and is subject to confirmatory due diligence, required government approvals and definitive documentation. Genenta is evolving into Saentra Forge, a strategic consolidator in biotech, defense, aerospace and Italian national-security sectors, with Sòphia HT described as already profitable and projecting EBITDA growth.